Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.42 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824198 | 0.97 | POLB (0.48) | POLBALDH1A1HTTL3MBTL1JAK2 | |
| SCHEMBL29418001 | 0.97 | POLB (0.48) | POLBALDH1A1HTTL3MBTL1JAK2 | |
| SCHEMBL9717234 | 0.80 | KDM4E (0.43) | POLBALDH1A1L3MBTL1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL897927 | 0.79 | RAPGEF4 (0.53) | POLBALDH1A1HTTL3MBTL1KDM4E | |
| Hydrochloric Acid SCHEMBL4587756 | 0.79 | KMT2A (0.45) | POLBALDH1A1HTTALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL3464344 | 0.79 | CYP1A2 (0.47) | POLBALDH1A1HTTKDM4EGAA | |
| Hydrochloric Acid SCHEMBL28652475 | 0.79 | ALDH1A1 (0.42) | POLBALDH1A1HTTL3MBTL1KDM4E | |
| Hydrochloric Acid SCHEMBL7406469 | 0.79 | GAA (0.41) | ALDH1A1JAK2GAAMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL16280191 | 0.79 | TSHR (0.50) | ALDH1A1KDM4EGAAALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL7876249 | 0.79 | NPC1 (0.48) | POLBHTTKDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024348-A | New preparation method of Artemisia princeps | 南通常佑药业科技有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-112321454-B | Eltrombopag intermediate, preparation method thereof and method for preparing Ai Qubo Pa by using same | 长沙创新药物工业技术研究院有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-112645879-B | Method for synthesizing Eltrombopag by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-112645879-A | Method for synthesizing Eltrombopag by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2021-04-13 | — | — | CN | claimed |
| CN-112321454-A | Elotriporpa intermediate, preparation method thereof and method for preparing Elotriporpa by using intermediate | 湖南华腾制药有限公司 | 2021-02-05 | — | — | CN | claimed |
| CN-106831584-B | A kind of efficient method for preparing tri- substituted pyrazolecarboxylic class compound of 1,3,5- | 江西师范大学 | 2019-11-22 | — | — | CN | claimed |
| CN-109438359-A | A kind of preparation method of 3- methyl-1-(3,4- 3,5-dimethylphenyl)-2- pyrazolin-5-one hydrochloride | 刘飞 | 2019-03-08 | — | — | CN | claimed |
| CN-104478804-B | Double nitrogen-containing heterocycle compounds and its preparation method and application | 河南大学 | 2016-08-17 | — | — | CN | claimed |
| CN-104725318-A | Synthetic method of eltrombopag olamine | BEIJING LABWORLD BIO MEDICINE TECHNOLOGY CO LTD | 2015-06-24 | — | — | CN | claimed |
| CN-104628647-A | Preparation method of 3-methyl-1-(3,4-dimethylphenyl)-2-pyrazoline-5-one | SHANGHAI INST PHARM INDUSTRY | 2015-05-20 | — | — | CN | claimed |
| CN-104478804-A | Nitrogen-containing bisheterocyclic compound, and preparation method and application thereof | UNIV HENAN | 2015-04-01 | — | — | CN | claimed |
| CN-102731404-B | Double-pyrazole ring compound and derivative, preparation method and application thereof | UNIV HENAN | 2014-06-11 | — | — | CN | claimed |
| CN-102731477-B | Pyrazoloquinoline compound and derivatives thereof, as well as preparation method and application thereof | UNIV HENAN | 2014-02-05 | — | — | CN | claimed |
| CN-102731404-A | Double-pyrazole ring compound and derivative, preparation method and application thereof | UNIV HENAN | 2012-10-17 | — | — | CN | claimed |
| CN-102731477-A | Pyrazoloquinoline compound and derivatives thereof, as well as preparation method and application of pyrazoloquinoline compound and derivatives thereof | UNIV HENAN | 2012-10-17 | — | — | CN | claimed |
| CN-102070486-A | Method for synthesizing 2,4-dimethyl phenylhydrazine hydrochloride | UNIV TIANJIN POLYTECHNIC | 2011-05-25 | — | — | CN | claimed |
| EP-0918052-B1 | Improved polymeric mdi color | BAYER AG (US) | 2003-05-28 | — | — | EP | claimed |
| US-5942151-A | PREVENTING THE DISCOLORATION OF PRODUCING POLYMETHYLENEPOLYPHENYLENE POLYISOCYANATE BY ADDING AN ADDITIVE HYDRAZINE OR A HYDRAZINE DERIVATIVE | BAYER CORPORATION (US) | 1999-08-24 | — | — | US | claimed |
| EP-0918052-A1 | Improved polymeric mdi color | Bayer Corporation (US) | 1999-05-26 | — | — | EP | claimed |
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | LOMOND THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4416146-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-C] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | Lomond Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118076605-A | Substituted 1H-pyrazolo [4,3-c ] quinolines, methods of preparation and uses thereof | 洛蒙治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117024348-A | New preparation method of Artemisia princeps | 南通常佑药业科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-115974844-B | 3,4, 5-trimethoxyphenyl derivative and application thereof | 广东省科学院动物研究所 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023064133-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | LOMOND THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-115974844-A | 3,4,5-trimethoxyphenyl derivative and application thereof | 广东省科学院动物研究所 | 2023-04-18 | — | — | CN | disclosed |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| CN-112321454-B | Eltrombopag intermediate, preparation method thereof and method for preparing Ai Qubo Pa by using same | 长沙创新药物工业技术研究院有限公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-115611823-A | 1,2, 4-triazole-phenyl hydroxamic acid compound, preparation method and application | 新天地医药技术研究院(郑州)有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-113582946-B | 3-aryl-5-thio-1,3,4-thiadiazole-2-thioketone derivative and preparation method and application thereof | 赣南师范大学（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-111454160-B | Beta-trifluoromethylaniline compound and preparation method thereof | 赣南师范大学 | 2022-10-28 | — | — | CN | disclosed |
| CN-112979481-B | Preparation method of eltrombopag intermediate and preparation method of eltrombopag diethanolamine salt | 浙江农林大学 | 2022-06-21 | — | — | CN | disclosed |
| EP-3999057-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES SAS (FR) | 2022-05-25 | — | — | EP | disclosed |
| CN-114478382-A | Isoquinoline-3-hydrazide compound and preparation method and application thereof | 贵州大学 | 2022-05-13 | — | — | CN | disclosed |
| EP-3258929-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-112645879-B | Method for synthesizing Eltrombopag by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-112645879-B | Method for synthesizing Eltrombopag by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114144410-A | Polyarylurea derivatives and their use in the treatment of muscular diseases | 阿纳格纳斯生物技术股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-113582946-A | 3-aryl-5-thio-1, 3, 4-thiadiazole-2-thioketone derivative and preparation method and application thereof | 赣南师范大学 | 2021-11-02 | — | — | CN | disclosed |
| CN-112979481-A | Preparation method of Eltrombopag intermediate and preparation method of Eltrombopag diethanolamine salt | 浙江农林大学 | 2021-06-18 | — | — | CN | disclosed |
| CN-112645879-A | Method for synthesizing Eltrombopag by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112645879-A | Method for synthesizing Eltrombopag by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112321454-A | Elotriporpa intermediate, preparation method thereof and method for preparing Elotriporpa by using intermediate | 湖南华腾制药有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2021013712-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2021-01-28 | — | — | WO | disclosed |
| CN-111650812-A | Coloring composition, optical filter and display device obtained by using same | 日本化药株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-111454160-A | β -trifluoromethylaniline compound and preparation method thereof | 赣南师范大学 | 2020-07-28 | — | — | CN | disclosed |
| CN-106831584-B | A kind of efficient method for preparing tri- substituted pyrazolecarboxylic class compound of 1,3,5- | 江西师范大学 | 2019-11-22 | — | — | CN | disclosed |
| WO-2019188456-A1 | NOVEL ANTI-TUMOR AGENT | 学校法人 川崎学園 | 2019-10-03 | — | — | WO | disclosed |
| US-10351558-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10336706-B2 | Crystalline form of Eltrombopag free acid | HETERO RESEARCH FOUNDATION (IN) | 2019-07-02 | — | — | US | disclosed |
| CN-109438359-A | A kind of preparation method of 3- methyl-1-(3,4- 3,5-dimethylphenyl)-2- pyrazolin-5-one hydrochloride | 刘飞 | 2019-03-08 | — | — | CN | disclosed |
| CN-106008125-B | A kind of method of environmentally protective synthesizing amide key | 江西师范大学 | 2018-10-30 | — | — | CN | disclosed |
| US-20180022747-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-25 | — | — | US | disclosed |
| EP-3004097-B1 | KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2018-01-17 | — | — | EP | disclosed |
| EP-3258929-A1 | FACTOR IXa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170275255-A1 | CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID | HETERO RESEARCH FOUNDATION (IN) | 2017-09-28 | — | — | US | disclosed |
| EP-3188737-A1 | CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID | Hetero Research Foundation (IN) | 2017-07-12 | — | — | EP | disclosed |
| US-9701670-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| CN-106831584-A | Method for efficiently preparing 1,3, 5-trisubstituted pyrazole compound | 江西师范大学 | 2017-06-13 | — | — | CN | disclosed |
| CN-104710419-B | Tetrahydropyridine [4,3-b] diindyl compound as well as preparation method and pharmaceutical application thereof | 中国药科大学 | 2017-05-24 | — | — | CN | disclosed |
| CN-106349187-A | Environment-friendly method for synthesizing amido bond | 江西师范大学 | 2017-01-25 | — | — | CN | disclosed |
| CN-103360317-B | Bicycle substituted pyrazolone azo analog derivative, Preparation Method And The Use | 齐鲁制药有限公司 | 2016-12-14 | — | — | CN | disclosed |
| EP-2885284-B1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| CN-104892720-B | 4,4-dimethyl lithocholic acid-2,3-a pair of horses going side by side N-arylpyrazole derivative and its preparation method and application | 华东师范大学 | 2016-10-26 | — | — | CN | disclosed |
| CN-106008125-A | Environment-friendly amido bond synthesis method | 江西师范大学 | 2016-10-12 | — | — | CN | disclosed |
| EP-2842955-B1 | TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-9440927-B2 | Process for preparation of substituted 3'-hydroazino-diphenyl-3-carboxylic acid compounds | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| US-9440974-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-13 | — | — | US | disclosed |
| WO-2016133793-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | WO | disclosed |
| CN-104478804-B | Double nitrogen-containing heterocycle compounds and its preparation method and application | 河南大学 | 2016-08-17 | — | — | CN | disclosed |
| CN-102026985-B | Quinazoline derivatives as RAF kinase modulators and methods and uses thereof | 埃姆比特生物科学公司 | 2016-07-06 | — | — | CN | disclosed |
| EP-3004097-A1 | KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2016-04-13 | — | — | EP | disclosed |
| WO-2016035018-A1 | CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID | HETERO RESEARCH FOUNDATION (IN) | 2016-03-10 | — | — | WO | disclosed |
| CN-105377847-A | Kinase inhibitors | CHIESI FARM SPA | 2016-03-02 | — | — | CN | disclosed |
| US-9242977-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20160016953-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A (IT) | 2016-01-21 | — | — | US | disclosed |
| CN-104130190-B | A kind of synthetic method of pyrazole derivatives | TAIZHOU UNIVERSITY (CN) | 2016-01-06 | — | — | CN | disclosed |
| US-9181242-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-10 | — | — | US | disclosed |
| CN-102977095-B | Pyrazolo quinolines and uses thereof | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-10-28 | — | — | CN | disclosed |
| CN-104892720-A | 4,4-dimethyllithocholato-2,3-N-arylpyrazole derivatives and preparation method and application thereof | UNIV EAST CHINA NORMAL | 2015-09-09 | — | — | CN | disclosed |
| US-20150218137-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| EP-2885284-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | Respivert Limited (GB) | 2015-06-24 | — | — | EP | disclosed |
| CN-104725318-A | Synthetic method of eltrombopag olamine | BEIJING LABWORLD BIO MEDICINE TECHNOLOGY CO LTD | 2015-06-24 | — | — | CN | disclosed |
| CN-104725318-A | Synthetic method of eltrombopag olamine | BEIJING LABWORLD BIO MEDICINE TECHNOLOGY CO LTD | 2015-06-24 | — | — | CN | disclosed |
| CN-104710419-A | Tetrahydropyridine [4,3-b] diindyl compound as well as preparation method and pharmaceutical application thereof | UNIV CHINA PHARMA | 2015-06-17 | — | — | CN | disclosed |
| CN-104628647-A | Preparation method of 3-methyl-1-(3,4-dimethylphenyl)-2-pyrazoline-5-one | SHANGHAI INST PHARM INDUSTRY | 2015-05-20 | — | — | CN | disclosed |
| US-20150111865-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-23 | — | — | US | disclosed |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2015-04-02 | — | — | US | disclosed |
| CN-104478804-A | Nitrogen-containing bisheterocyclic compound, and preparation method and application thereof | UNIV HENAN | 2015-04-01 | — | — | CN | disclosed |
| US-20150087845-A1 | PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDROAZINO-DIPHENYL-3-CARBOXYLIC ACID COMPOUNDS | GLENMARK GENERICS LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| EP-2842955-A1 | Trk-INHIBITING COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20140364412-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| WO-2014195402-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | WO | disclosed |
| CN-104130190-A | Synthetic method of pyrazole derivatives | UNIV TAIZHOU | 2014-11-05 | — | — | CN | disclosed |
| EP-2755955-A2 | PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDRAZINO-BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS | Glenmark Generics Limited (IN) | 2014-07-23 | — | — | EP | disclosed |
| CN-102731404-B | Double-pyrazole ring compound and derivative, preparation method and application thereof | UNIV HENAN | 2014-06-11 | — | — | CN | disclosed |
| US-20140057915-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-02-27 | — | — | US | disclosed |
| WO-2014027209-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-02-20 | — | — | WO | disclosed |
| CN-102731477-B | Pyrazoloquinoline compound and derivatives thereof, as well as preparation method and application thereof | UNIV HENAN | 2014-02-05 | — | — | CN | disclosed |
| CN-103360317-A | Dicyclo-substituted pyrazolone azo derivatives, as well as preparation method and use thereof | QILU PHARMACEUTICAL CO LTD | 2013-10-23 | — | — | CN | disclosed |
| WO-2013072921-A2 | PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDRAZINO-BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS | GLENMARK GENERICS LIMITED (IN) | 2013-05-23 | — | — | WO | disclosed |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| CN-102977095-A | Pyrroloquinolines compound and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2013-03-20 | — | — | CN | disclosed |
| US-8372822-B2 | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof | PLIVA HRVATSKA D.O.O. (HR) | 2013-02-12 | — | — | US | disclosed |
| CN-102731404-A | Double-pyrazole ring compound and derivative, preparation method and application thereof | UNIV HENAN | 2012-10-17 | — | — | CN | disclosed |
| CN-102731477-A | Pyrazoloquinoline compound and derivatives thereof, as well as preparation method and application of pyrazoloquinoline compound and derivatives thereof | UNIV HENAN | 2012-10-17 | — | — | CN | disclosed |
| US-20120238612-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | PLIVA HRVATSKA D.O.O. (HR) | 2012-09-20 | — | — | US | disclosed |
| US-8217021-B2 | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof | PLIVA HRVATSKA D.O.O. (HR) | 2012-07-10 | — | — | US | disclosed |
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2414336-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | Pliva Hrvatska D.O.O. (HR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022124-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | PLIVA HRVATSKA D.O.O. (HR) | 2012-01-26 | — | — | US | disclosed |
| US-8022093-B2 | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof | PLIVA HRVATSKA D.O.O. (HR) | 2011-09-20 | — | — | US | disclosed |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC. | 2011-09-01 | — | — | US | disclosed |
| US-20110196008-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | PLIVA HRVATSKA D.O.O. (HR) | 2011-08-11 | — | — | US | disclosed |
| US-7956048-B2 | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof | PLIVA HRVATSKA D.O.O. (HR) | 2011-06-07 | — | — | US | disclosed |
| CN-102070486-A | Method for synthesizing 2,4-dimethyl phenylhydrazine hydrochloride | UNIV TIANJIN POLYTECHNIC | 2011-05-25 | — | — | CN | disclosed |
| CN-102026985-A | Quinazoline derivatives as RAF kinase modulators and methods and uses thereof | AMBIT BIOSCIENCES CORPORATON | 2011-04-20 | — | — | CN | disclosed |
| CN-101965350-A | Novel pyrazolo [3,4-d ] pyrimidine derivatives as anticancer agents | NATCO PHARMA LTD | 2011-02-02 | — | — | CN | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010114943-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | PLIVA HRVATSKA D.O.O. (HR) | 2010-10-07 | — | — | WO | disclosed |
| US-20100256212-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | PLIVA HRVATSKA D.O.O. (HR) | 2010-10-07 | — | — | US | disclosed |
| US-7790704-B2 | Thrombopoietin mimetics | GlaxoSmithKline, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7674887-B2 | Thrombopoietin mimetics | GLAXOSMITHKLINE LLC (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-2086551-A2 | THROMBOPOIETIN MIMETICS | Stategics, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1864981-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090176973-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2009-07-09 | — | — | US | disclosed |
| US-20090155203-A1 | THROMBOPOIETIN MIMETICS | SmithKline Bee cham Corporation | 2009-06-18 | — | — | US | disclosed |
| US-7473686-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7439342-B2 | Thrombopoietin mimetics | SMITH KLINE BEECHAM CORP. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080214640-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2008-09-04 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070583-A2 | THROMBOPOIETIN MIMETICS | STATEGICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080090996-A1 | Hydroxy-1-azobenzene derivatives, for example, 4'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-3'-hydroxybiphenyl-4-carboxylic acid; 3'-Amino-2'-hydroxybiphenyl-3-carboxylic acid; thrombocytopenia treatment | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| EP-1910361-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7335649-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1351979-B1 | REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1294378-B1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2007-08-02 | — | — | US | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| WO-2007016353-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027178-A1 | Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-01 | — | — | US | disclosed |
| US-7160870-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1370252-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1351979-A4 | REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6875786-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040077855-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20040053299-A1 | Regulated activation of cell-membrane receptors by metal-chelating agonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1370252-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1351979-A1 | REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-0918052-B1 | Improved polymeric mdi color | BAYER AG (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6518273-B1 | 2-aryl indole derivative as antagonists of tachykinins | MERCK SHARP & DOHME LTD. | 2003-02-11 | — | — | US | disclosed |
| WO-2002085343-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002057300-A1 | REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2000051984-A1 | 2-ARYL INDOLE DERIVATIVES AS ANTAGONISTS OF TACHYKININS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
| US-5942151-A | PREVENTING THE DISCOLORATION OF PRODUCING POLYMETHYLENEPOLYPHENYLENE POLYISOCYANATE BY ADDING AN ADDITIVE HYDRAZINE OR A HYDRAZINE DERIVATIVE | BAYER CORPORATION (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0918052-A1 | Improved polymeric mdi color | Bayer Corporation (US) | 1999-05-26 | — | — | EP | disclosed |
| CN-1033029-C | Indenoindole compounds II | UNIV BATH (GB) | 1996-10-16 | — | — | CN | disclosed |
| US-5484940-A | ULTRAVIOLET RADIATION ABSORBERS FOR PLASTICS, AMYLOID PEPTIDE INHIBITORS, ALZHEIMER*S DISEASE | ATHENA NEUROSCIENCES, INC. | 1996-01-16 | — | — | US | disclosed |
| US-5288877-A | Continuous process for preparing indolenine compounds | PPG INDUSTRIES, INC. (US) | 1994-02-22 | — | — | US | disclosed |
| US-4257952-A | PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4172834-A | ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS | STERLING DRUG INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077855-A1 | Thrombopoietin mimetics | MPL, THPO, TEK | JAK2 101/4885GAA 2814/4885POLB 2719/4885 |
| US-20070027178-A1 | Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists | HTR2B, HTR1A, HTR3B | JAK2 546/4885GAA 1854/4885POLB 2336/4885 |
| US-20040053299-A1 | Regulated activation of cell-membrane receptors by metal-chelating agonists | CASR, TRPM8, TRPM6 | JAK2 2985/4885GAA 2634/4885POLB 4781/4885 |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | JAK2 59/4885GAA 2853/4885POLB 2219/4885 |
| US-20120022124-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | THPO, MPL, PTGER1 | JAK2 221/4885GAA 2807/4885POLB 1659/4885 |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | JAK2 59/4885GAA 2853/4885POLB 2219/4885 |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | JAK2 59/4885GAA 2853/4885POLB 2219/4885 |
| US-10336706-B2 | Crystalline form of Eltrombopag free acid | ACKR3, PLG, GCG | JAK2 2892/4885GAA 557/4885POLB 3733/4885 |
| US-20160016953-A1 | KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K6 | JAK2 123/4885GAA 2021/4885POLB 1153/4885 |
| US-20180022747-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | JAK2 515/4885GAA 1226/4885POLB 3869/4885 |
| US-20170275255-A1 | CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID | ACKR3, PLG, GCG | JAK2 2892/4885GAA 557/4885POLB 3733/4885 |
| US-20150218137-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | SYK, BTK, LYN | JAK2 74/4885GAA 3784/4885POLB 2754/4885 |
| US-20150087845-A1 | PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDROAZINO-DIPHENYL-3-CARBOXYLIC ACID COMPOUNDS | CYP3A5, UGT1A3, HPD | JAK2 770/4885GAA 294/4885POLB 1649/4885 |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | JAK2 59/4885GAA 2853/4885POLB 2219/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | JAK2 59/4885GAA 2853/4885POLB 2219/4885 |
| US-20090155203-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | JAK2 59/4885GAA 2853/4885POLB 2219/4885 |
| US-20100256212-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | THPO, MPL, PTGER1 | JAK2 221/4885GAA 2807/4885POLB 1659/4885 |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | CKMT1A; CKMT1B, TNNC1, UBQLN2 | JAK2 3832/4885GAA 627/4885POLB 1305/4885 |
| US-20080139621-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | JAK2 80/4885GAA 4055/4885POLB 2851/4885 |
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | FLT3, PDXK, PHKG1 | JAK2 154/4885GAA 2598/4885POLB 1320/4885 |
| US-20090176973-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | JAK2 59/4885GAA 2853/4885POLB 2219/4885 |
| US-20100323965-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | JAK2 80/4885GAA 4055/4885POLB 2851/4885 |
| US-20120238612-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | THPO, MPL, PTGER1 | JAK2 221/4885GAA 2807/4885POLB 1659/4885 |
| US-20150111865-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TEC | JAK2 764/4885GAA 2302/4885POLB 3705/4885 |
| US-20140364412-A1 | KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K6 | JAK2 123/4885GAA 2021/4885POLB 1153/4885 |
| US-20140057915-A1 | KINASE INHIBITORS | SYK, BTK, LYN | JAK2 66/4885GAA 2521/4885POLB 2839/4885 |
| US-10351558-B2 | Factor IXa inhibitors | F9, TFPI, F12 | JAK2 515/4885GAA 1226/4885POLB 3869/4885 |
| US-20110196008-A1 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF | THPO, MPL, PTGER1 | JAK2 221/4885GAA 2807/4885POLB 1659/4885 |
| US-20080214640-A1 | Thrombopoietin mimetics | MPL, THPO, TEK | JAK2 59/4885GAA 2853/4885POLB 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.